Cargando…

Evaluation of α-Synuclein and Apolipoprotein E as Potential Biomarkers in Cerebrospinal Fluid to Monitor Pharmacotherapeutic Efficacy in Dopamine Dictated Disease States of Parkinson’s Disease and Schizophrenia [Corrigendum]

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249345/ https://www.ncbi.nlm.nih.gov/pubmed/35784514 http://dx.doi.org/10.2147/NDT.S379262

Ejemplares similares

Evaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson’s disease and schizophrenia
por: Gupta, Ashish Kumar, et al.
Publicado: (2019)

Cerebrospinal Fluid Proteomics For Identification Of α2-Macroglobulin As A Potential Biomarker To Monitor Pharmacological Therapeutic Efficacy In Dopamine Dictated Disease States Of Parkinson’s Disease And Schizophrenia
por: Gupta, Ashish Kumar, et al.
Publicado: (2019)

Role of Apolipoproteins and α-Synuclein in Parkinson’s Disease
por: Emamzadeh, Fatemeh Nouri
Publicado: (2017)

Longitudinal Analyses of Cerebrospinal Fluid α-Synuclein in Prodromal and Early Parkinson’s Disease
por: Mollenhauer, Brit, et al.
Publicado: (2019)

Corrigendum to: Cerebrospinal fluid liquid biopsy for detecting somatic mosaicism in brain
Publicado: (2021)

Baseline Cerebrospinal Fluid α-Synuclein in Parkinson’s Disease Is Associated with Disease Progression and Cognitive Decline
por: Emdina, Anna, et al.
Publicado: (2022)

The Convergence of Dopamine and α-Synuclein: Implications for Parkinson’s Disease
por: Mor, Danielle E, et al.
Publicado: (2018)

Cerebrospinal Fluid Lysosomal Enzymes and Alpha-Synuclein in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

Elevated Levels of α-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naïve Patients with Parkinson's Disease
por: Park, Min Jeong, et al.
Publicado: (2011)

α‐synuclein RT‐QuIC in cerebrospinal fluid of LRRK2‐linked Parkinson's disease
por: Garrido, Alicia, et al.
Publicado: (2019)

Comparative study of cerebrospinal fluid α‐synuclein seeding aggregation assays for diagnosis of Parkinson's disease
por: Kang, Un Jung, et al.
Publicado: (2019)

Corrigendum to “Alzheimer's Disease Dementia as the Diagnosis Best Supported by the Cerebrospinal Fluid Biomarkers: Difference in Cut-Off Levels from Thai Experience”
por: Senanarong, Vorapun, et al.
Publicado: (2017)

Parkinson’s disease managing reversible neurodegeneration [Corrigendum]
Publicado: (2016)

Mini Review: Correlations of Cognitive Domains With Cerebrospinal Fluid α-Synuclein Levels in Patients With Parkinson's Disease
por: Murakami, Hidetomo, et al.
Publicado: (2021)

Evaluation of Serum Apolipoprotein E as a Potential Biomarker for Pharmacological Therapeutic Efficacy Monitoring in Dopamine Dictated Disease Spectrum of Schizophrenia and Parkinson’s disease: A Preliminary Study
por: Gupta, Ashish Kumar, et al.
Publicado: (2018)

Corrigendum: Evaluation of cerebrospinal fluid neurofilament light chain levels in multiple sclerosis and non-demyelinating diseases of the central nervous system: clinical and biochemical perspective
Publicado: (2023)

The Diagnostic and Differential Diagnosis Utility of Cerebrospinal Fluid α-Synuclein Levels in Parkinson's Disease: A Meta-Analysis
por: Zhou, Bo, et al.
Publicado: (2015)

α-synuclein−lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients
por: Paslawski, Wojciech, et al.
Publicado: (2019)

Baseline concentration of misfolded α‐synuclein aggregates in cerebrospinal fluid predicts risk of cognitive decline in Parkinson's disease
por: Ning, H., et al.
Publicado: (2018)

Orexin/hypocretin levels in the cerebrospinal fluid and characteristics of patients with myotonic dystrophy type 1 with excessive daytime sleepiness [Corrigendum]
Publicado: (2018)

Effect of superparamagnetic nanoparticles coated with various electric charges on α-synuclein and β-amyloid proteins fibrillation process [Corrigendum]
Publicado: (2019)

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2014)

Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study
por: Unterberger, Ursula, et al.
Publicado: (2014)

The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer’s disease
por: Twohig, Daniel, et al.
Publicado: (2018)

Amino acid management of Parkinson’s disease: a case study [Corrigendum]
Publicado: (2016)

Corrigendum to: Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson’s disease
Publicado: (2020)

Does TRODAT-1 SPECT Uptake Correlate with Cerebrospinal Fluid α-Synuclein Levels in Mid-Stage Parkinson’s Disease?
por: Coutinho, Artur M., et al.
Publicado: (2023)

α‐Synuclein real‐time quaking‐induced conversion in the cerebrospinal fluid of uncertain cases of parkinsonism
por: van Rumund, Anouke, et al.
Publicado: (2019)

Corrigendum to “Functional Improvements in Parkinson's Disease Following a Randomized Trial of Yoga”
por: Van Puymbroeck, Marieke, et al.
Publicado: (2018)

Corrigendum to: Imaging protein aggregates in the serum and cerebrospinal fluid in Parkinson’s disease
Publicado: (2021)

Single‐Molecule Counting Coupled to Rapid Amplification Enables Detection of α‐Synuclein Aggregates in Cerebrospinal Fluid of Parkinson's Disease Patients
por: Bhumkar, Akshay, et al.
Publicado: (2021)

Cerebrospinal Fluid α-Synuclein Species in Cognitive and Movements Disorders
por: Constantinides, Vasilios C., et al.
Publicado: (2021)

Impact of Supporting People with Advanced Parkinson’s Disease on Carer’s Quality of Life and Burden [Corrigendum]
Publicado: (2021)

Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels
por: Ibanez, Laura, et al.
Publicado: (2017)

Corrigendum: Fluid responsiveness in the pediatric population
por: Lee, Ji-Hyun, et al.
Publicado: (2019)

Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients
por: Lennol, Matthew Paul, et al.
Publicado: (2022)

Corrigendum to “Subjective Experiences of Speech and Language Therapy in Patients with Parkinson's Disease: A Pilot Study”
por: Spurgeon, Laura, et al.
Publicado: (2016)

The Future of Schizophrenia Pharmacotherapeutics: Not So Bleak
por: Carpenter, William T.
Publicado: (2012)

The N terminus of α-synuclein dictates fibril formation
por: McGlinchey, Ryan P., et al.
Publicado: (2021)

Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease
por: Kruse, Niels, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_n16n8chp2f4rh96bo0h9c9m3gh